Artiva Biotherapeutics Reports Preliminary Cash and Investments of $319.10 Million
The company reported preliminary cash, cash equivalents and investments of $319.10 million as of September 30, 2026.
Related stories
Coinbase Posts Third-Quarter Profit as Crypto Trading Rebounds
Coinbase reported a quarterly profit of $718.7 million, or $2.51 per share, for the quarter ended September. The profit ended a three-quarter streak of losses as heightened digital
M impact | EQUITY | Oct 29, 2026, 08:29 PM UTC
Alignment Healthcare Q3 Revenue Beats; Cuts FY Adjusted Core Profit Outlook
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
Rimini Street Q3 Revenue Beats Analyst Estimates
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
Walmart Commits About $6 Billion to Expand Symbotic Deal
Symbotic said Walmart expanded their agreement, committing about $6 billion over several years to deploy additional supply-chain automation technology across its distribution netwo
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
U.S. Stocks Fall as Alphabet Slide Weighs on AI Optimism
U.S. stocks declined after Alphabet’s revenue shortfall drove one of the largest one-session market-capitalization drops for a single company on record, raising doubts about AI inf
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
Rivian Q3 Revenue Beats Estimates, Raises 2026 Delivery Guidance
Rivian reported Q3 revenue above estimates, citing R2 model demand, and raised its 2026 car-delivery guidance.
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC